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Background
The use of HAART during lactation has also been dis-
cussed as an approach to reduce postnatal HIV-1 trans-
mission. The benefits and safety of HAART used solely
for prevention of postnatal transmission in healthy HIV
infected women have not yet been demonstrated in clin-
ical trials. The extension of maternal HAART through
the period of breast feeding can be proposed as pivotal
strategy to reduce breast milk HIV transmission.
Objectives
To assess the safety of breastfeeding during antiretro-
viral treatment in terms of virological and clinical out-
comes in pregnant HIV-infected women in the Dodoma
area of the United Republic of Tanzania. Secondary
objective is the study of viral dynamic and therapeutic
drug monitoring of antiretroviral drugs into breast milk
of HIV-infected women treated with HAART during
breastfeeding.
Results
The enrolment phase of the AMANI Study started on
May 2010 at Makole Health Centre (Makole UHC).
After the first two months 68 HIV positive pregnant
women (HPW) out of 68(100%) HCWs attending the
site were counseled. 50 HPW (73.5%) were enroled in
the study and are being followed up at Makole UHC. Of
the remaining 16(23.5%) were not eligible and only 2
(2.9%) refused to participate. Among the 50 HPW
enroled only 6 (12%) have opted not to breastfeed after
delivery, 12 HPW have started HAART prophylaxis
from the 28 weeks of gestation, 3 HPW were found eli-
gible and started HAART. 1 HPW has given birth on
16th July 2010 with no fetal and maternal complication.
No patient reported any side effects to the ARV drugs.
Conclusions
At the moment the study is progressing over the expec-
tation. The procedures of the study where well accepted
by the local Health Personnel with the totality of the
HPWs counseled and by the HPW with only the 2.9%
of refusal. Data from the study show that this kind of
implementation research is well accepted by the Health
personnel in terms of capacity building and by the
HPW in terms of compliance and acceptance of the
treatment. The benefits of the expanded treatment are
well understood and overtake the discomfort of a higher
pill burden and the risk of more adverse events.
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